<DOC>
	<DOCNO>NCT00551590</DOCNO>
	<brief_summary>The purpose study assess effect DPP-4 inhibitor sitagliptin incretin effect patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Effect Sitagliptin Incretin Effect Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Following meal , gut-produced incretin hormone glucagon-like peptide-1 ( GLP-1 ) glucose-dependent insulinotropic polypeptide ( GIP ) release circulation . Because GLP-1 GIP mediate grossly 60 % insulin-stimulatory action , so-called incretin effect , crucial component natural endogenous system guarantee glucose homeostasis . In addition , GLP-1 lower glucagon secretion pancreatic alpha-cells delay nutrient delivery stomach inhibit gastric emptying . The rise insulin concentration enhances glucose clearance peripheral tissue muscle , low glucagon concentration combine rise insulin reduces hepatic glucose production . By enhance glucose clearance lower hepatic glucose production , post-meal glucose excursion reduce . Both GLP-1 GIP degrade enzyme dipeptidylpeptidase-4 ( DPP-4 ) . Inhibition DPP-4 specific DPP-4 inhibitor Sitagliptin increase plasma level GLP-1 GIP , reduce postprandial glycemia . Although important healthy subject , role incretin hormones patient T2DM unclear . In T2DM insulinotropic efficacy GIP reduce postprandial release GLP-1 diminish . Therefore , aim study T2DM quantify incretin effect without DPP-4 inhibitor sitagliptin . The specific GLP-1 receptor antagonist exendin ( 9-39 ) use quantify contribution GLP-1 GIP incretin effect patient T2DM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Women T2DM without childbearing potential Male patient T2DM use doublebarrier method contraception must able complete 1 week washout current antidiabetic medication ( patient PPARγ must least 4 week ) medication may alter gastric motility ( i.e . acetaminophen , erythromycin ) except cardiac medication stable dose . Age 3070 year HbA1c ≤9 % screen BMI &lt; 40 kg/m2 Must fast blood glucose ≤11.1 mmol/L ( 200 mg/dL ) screen Able provide write informed consent prior study participation Able communicate well investigator comply requirement study Able maintain dietetic restriction perform measurement blood glucose daily basis ( fast twohours postprandial ) . Patients must inform investigator fast glucose 200mg/dl two hour postprandially blood glucose concentration 240mg/dl measure . T1DM , diabetes result pancreatic injury , secondary form diabetes ( eg . Cushing , acromegaly ) Females childbearing potential , breastfeed pregnant woman Need insulin within previous 3 month Use Thiazolidinediones previous 4 week Significant concomitant disease complication diabetes ( i.e . nephropathy , autonomic dysfunction , orthostasis ) . Fasting triglyceride &gt; 5.1 mmol/L ( &gt; 450 mg/dL ) within past 4 week . Treatment systemic steroid thyroid hormone ( unstable dosage ) . Patients history gastrointestinal surgery , e.g . partial bowel resection , partial gastric resection , etc . Participation clinical investigation within 4 week prior dose longer required local regulation . Donation loss 400 mL blood within 8 week prior dose . Significant illness within two week prior dose . Past medical history clinically significant ECG abnormality family history prolong QTinterval syndrome . History clinically significant drug allergy ; history atopic allergy ( asthma , urticaria , eczematous dermatitis ) . A known hypersensitivity study drug drug similar study drug . Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug may jeopardize subject case participation study . The investigator guide evidence following : history inflammatory bowel syndrome , gastritis , ulcer , gastrointestinal rectal bleeding ; history major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection ; history clinical evidence pancreatic injury pancreatitis ; history presence impair renal function indicate abnormal creatinine urea value abnormal urinary constituent ( e.g. , albuminuria ) ; evidence urinary obstruction difficulty void screen ; Polymorphonuclears &lt; 1500/µL inclusion platelet count &lt; 100,000/μL screen baseline . History immunocompromise . Evidence liver disease indicate abnormal liver function test SGOT , SGPT , GGT , alkaline phosphatase , serum bilirubin . SGOT , SGPT , GGT alkaline phosphatase must exceed twice upper limit normal range , serum bilirubin exceed value 27 µmol/L ( 1.6 mg/dL ) . History drug alcohol abuse within 12 month prior dose evidence abuse indicate laboratory assay conduct screen evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>diabetes mellitus</keyword>
	<keyword>DPP-4 inhibitor</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>exendin ( 9-39 )</keyword>
	<keyword>GLP-1</keyword>
</DOC>